Clinical trial

S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid…

NCT00023777 · SWOG Cancer Research Network, Other · Completed

Key facts

NCT number NCT00023777
Title S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
Official title A Phase II Study Of Daunomycin And ARA-C, Both Given By Continous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older
Lead sponsor SWOG Cancer Research Network, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Leukemia
Intervention type Biological, Drug
Interventions filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride
Enrollment 71
Start date Aug 1, 2001
Primary completion Jun 1, 2003
Completion Apr 1, 2008
First posted Jan 27, 2003
Last update posted Mar 6, 2015
Countries United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies